1 |
Vlodavsky I, Folkman J, Sullivan R, et al. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A 1987;84:2292-6.
DOI
ScienceOn
|
2 |
Matsuzaki K, Yoshitake Y, Matuo Y, Sasaki H, Nishikawa K. Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. Proc Natl Acad Sci U S A 1989;86:9911-5.
DOI
ScienceOn
|
3 |
Dennis PA, Rifkin DB. Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumor growth. J Cell Physiol 1990;144:84-98.
DOI
|
4 |
Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65.
DOI
ScienceOn
|
5 |
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
DOI
ScienceOn
|
6 |
Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-93.
DOI
ScienceOn
|
7 |
Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9 Suppl 1:2-10.
DOI
|
8 |
Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861-5.
|
9 |
Vaisman N, Gospodarowicz D, Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 1990;265:19461-6.
|
10 |
Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992;89:244-53.
DOI
|
11 |
Volm M, Koomägi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997;74:64-8.
DOI
ScienceOn
|
12 |
Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-35.
|
13 |
Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
DOI
ScienceOn
|
14 |
Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 2005;106:3423-31.
DOI
ScienceOn
|
15 |
Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2005;131:624-30.
DOI
ScienceOn
|
16 |
Glen H, Mason S, Patel H, Macleod K, Brunton VG. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 2011;11:309.
DOI
ScienceOn
|
17 |
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
DOI
ScienceOn
|
18 |
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
DOI
ScienceOn
|
19 |
Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000;21:505-15.
DOI
ScienceOn
|
20 |
Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
DOI
ScienceOn
|
21 |
Moser C, Lang SA, Stoeltzing O. The direct effects of anti- vascular endothelial growth factor therapy on tumor cells. Clin Colorectal Cancer 2007;6:564-71.
DOI
ScienceOn
|
22 |
Jakeman LB, Armanini M, Phillips HS, Ferrara N. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993;133:848-59.
DOI
ScienceOn
|
23 |
Xia G, Kumar SR, Hawes D, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006;175:1245-52.
DOI
ScienceOn
|
24 |
Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 1993;91: 2235-43.
DOI
ScienceOn
|
25 |
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
|
26 |
Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001;98:1904-13.
DOI
ScienceOn
|
27 |
Su JL, Yen CJ, Chen PS, et al. The role of the VEGF-C /VEGFR-3 axis in cancer progression. Br J Cancer 2007;96:541-5.
DOI
ScienceOn
|
28 |
Park YW, Kwon KJ, Lee JW. Immunohistochemical study on expression of lymphangiogenic factors in oral cancer. J Korean Assoc Maxillofac Plast Reconstr Surg 2010;32:1-8.
|
29 |
Karkkainen MJ, Mäkinen T, Alitalo K. Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol 2002;4:E2-5.
DOI
|
30 |
Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122:664-71.
DOI
ScienceOn
|
31 |
Ikuta K, Yano S, Trung VT, et al. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res 2009;15:7229-37.
DOI
ScienceOn
|
32 |
Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275-88.
DOI
ScienceOn
|
33 |
Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14:5459-65.
DOI
ScienceOn
|
34 |
Ogino H, Hanibuchi M, Kakiuchi S, et al. E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. Mol Cancer Ther 2011;10:1218-28.
DOI
ScienceOn
|
35 |
Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8.
DOI
ScienceOn
|
36 |
Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-7.
DOI
ScienceOn
|
37 |
Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987;8:95-114.
DOI
ScienceOn
|
38 |
Esch F, Baird A, Ling N, et al. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci U S A 1985;82:6507-11.
DOI
ScienceOn
|
39 |
Jaye M, Howk R, Burgess W, et al. Human endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localization. Science 1986;233:541-5.
DOI
|
40 |
Gospodarowicz D, Thakral KK. Production a corpus luteum angiogenic factor responsible for proliferation of capillaries and neovascularization of the corpus luteum. Proc NatlAcad Sci U S A 1978;75:847-51.
DOI
ScienceOn
|